CAPPSID – an engineered partnership between bacteria and an oncolytic virus, has shown remarkable potential in effectively delivering cancer-fighting agents directly to malignant cells.
Imagine a modern-day Trojan Horse—engineered from living microbes—designed not to deceive an ancient city, but to outsmart cancer.
Traditional systemic treatments often struggle to penetrate solid tumours effectively. Although oncolytic viruses offer promise, the patient’s immune system usually detects and destroys them long before they can reach their target.
However, if two seemingly distinct allies—bacteria and viruses—could team up to overcome these challenges, the outcome would be completely different. This is precisely the idea behind CAPPSID: the Coordinated Activity of Prokaryote and Picornavirus for Safe Intracellular Delivery. This pioneering platform brings engineered bacteria and oncolytic virus together to deliver cancer-fighting agents directly into tumour cells with remarkable precision. CAPPSID – essentially a synthetic partnership between bacteria and an oncolytic virus, is demonstrating remarkable potential in effectively delivering cancer-fighting agents directly to malignant cells.
Bacteria as a Living Cloak
At the centre of CAPPSID is a specially engineered strain of Salmonella typhimurium. This bacterium has a natural preference to replicating within solid tumours, making it a highly effective delivery vehicle.
Its most striking feature is its role as a “synthetic capsid” – essentially a biological cloak shielding the viral payload. When given systemically (such as intravenously) the bacterium protects the virus from circulating antibodies that would normally neutralise it. This tackles a major shortcoming of conventional virotherapy—the barrier of pre-existing antiviral immunity.
Launching the Viral Weapon
Once the engineered Salmonella enter cancer cells, they become far more than passive carriers. They serve as intelligent internal launch systems. The bacteria are equipped with genetic circuits that sense whether they have entered a specific compartment of the host cell, known as the Salmonella-containing vacuole (SCV). When this environment is detected, promoters such as PsseA and PsseJ switch on and drive viral RNA production .
To ensure that viral RNA escapes into the host cell’s cytoplasm, the bacteria employ a controlled self-destruct mechanism. They produce two lytic proteins—Lysis protein E from phage φX174 and Hemolysin E (HlyE). These proteins rupture the bacterial membrane and puncture surrounding vacuole, allowing the bacteria to lyse and release viral genetic material directly into the tumour cell. This mechanism triggers a potent oncolytic viral infection exactly where it is needed.
Amplifying the Attack: Viral Spread
One of the limitations of bacteria-based cancer therapies is that bacterial replication tends to remain confined to the tumour core. Viruses, however, can spread. CAPPSID has been tested using Senecavirus A (SVA) – an oncolytic virus known to target neuroendocrine-like cells including H446 small-cell lung cancer.
In mouse models treated with S. typhimurium carrying the SVA system, researchers observed complete regression of tumours and a 100% survival rate for the treated mice, compared to control groups. Crucially, this efficacy was maintained even in fully immunocompetent mice that had previously developed antibodies against the virus, proving that the bacteria successfully cloaked the virus for systemic delivery. The active replication and spread of the virus to surrounding, bacteria-free cells significantly augment the overall therapeutic effect.
Safety with CAPPSID
While oncolytic viruses hold enormous promise, safety is always a concern—particularly the risk of uncontrolled viral spread. CAPPSID addresses this with an elegant control mechanism. The virus can be engineered so that its full maturation depends on an accessory enzyme delivered only by the bacteria. In this system, the virus requires the Tobacco Etch Virus protease (TEVp) to complete its life cycle and spread. The Salmonella deliver this protease alongside the viral RNA.
If TEVp is absent, the virus can replicate locally within the initially infected cells but cannot propagate further. This creates a confined, localised wave of viral activity that remains under bacterial control, substantially enhancing the safety profile.
Taken together, CAPPSID represents a multifaceted strategy that coordinates two microbial systems to overcome obstacles that limit bacteria-only or virus-only treatments. By combining precise tumour targeting with antibody cloaking and controlled viral spread, this system is paving way for safer and more effective next-generation virotherapies.
Keywords: engineered bacteria cancer therapy, oncolytic virus cancer treatment, bacterial virus cancer therapy, CAPPSID cancer therapy, innovative cancer treatments
Suggested Reads:
https://www.nature.com/articles/s41551-025-01476-https://www.insideprecisionmedicine.com/topics/oncology/virus-cloaked-in-bacteria-kills-tumor-cells-from-within/
